CABOZANTINIB News

CABOZANTINIB currently has 8 news articles, with 15 predicted indications.

This page combines the AI-predicted indications for CABOZANTINIB with the latest health news. Indications highlighted in orange have recent news coverage.

Drug Information

Evidence level: L5
Predicted indications (15):
- renal cell carcinoma (disease) (99.0%)
- clear cell renal carcinoma (99.0%)
- nonpapillary renal cell carcinoma (99.0%)
- medullary thyroid gland carcinoma (99.0%)
- renal cell adenocarcinoma (99.0%)
- liposarcoma (99.8%)
- ovarian myxoid liposarcoma (99.8%)
- unclassified renal cell carcinoma (99.8%)
- renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions (99.8%)
- renal cell carcinoma associated with neuroblastoma (99.8%)
- childhood kidney cell carcinoma (99.7%)
- renal carcinoma (99.7%)
- amyotrophic lateral sclerosis (99.7%)
- bilateral parasagittal parieto-occipital polymicrogyria (99.6%)
- angiolipoma (99.6%)